Subscribe To
Olympic steel, inc. (zeus) ceo richard marabito on q4 2021 results - earnings call transcript
Olympic Steel, Inc. (ZEUS) CEO Richard Marabito on Q4 2021 Results - Earnings Call Transcript...
February 25, 2022, 2:42 pm
Olympic steel, inc. (zeus) ceo richard marabito on q4 2021 results - earnings call transcript
Olympic Steel, Inc. (ZEUS) CEO Richard Marabito on Q4 2021 Results - Earnings Call Transcript...
February 25, 2022, 2:42 pm
Baird initiates coverage of tracon pharmaceuticals with a price target of $10
Baird said that it has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an outperform rating and a $10 price target. “We see a ...
February 23, 2022, 11:01 am
Baird initiates coverage of tracon pharmaceuticals with a price target of $10
Baird said that it has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an outperform rating and a $10 price target. “We see a ...
February 23, 2022, 11:01 am
Baird initiates coverage of tracon pharmaceuticals with a price target of $10
Baird said that it has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an outperform rating and a $10 price target. “We see a ...
February 23, 2022, 11:01 am
Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldo
NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...
February 18, 2022, 6:30 am
Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldo
NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...
February 18, 2022, 6:30 am
Immunic, inc. to present preclinical data for vidofludimus calcium at the 17th congress of european crohn's and colitis organization and announces blinded baseline characteristics of its phase 2 caldo
NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective ...
February 18, 2022, 6:30 am
Cinemark to host fourth quarter and full year 2021 earnings conference call
PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. (“Cinemark”) (NYSE: CNK), one of the largest motion picture exhi...
February 14, 2022, 5:23 pm
Cinemark to host fourth quarter and full year 2021 earnings conference call
PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. (“Cinemark”) (NYSE: CNK), one of the largest motion picture exhi...
February 14, 2022, 5:23 pm
Cinemark to host fourth quarter and full year 2021 earnings conference call
PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. (“Cinemark”) (NYSE: CNK), one of the largest motion picture exhi...
February 14, 2022, 5:23 pm
Effector therapeutics to present at 2022 bio ceo & investor conference
SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pio...
February 9, 2022, 4:00 pm
Effector therapeutics to present at 2022 bio ceo & investor conference
SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pio...
February 9, 2022, 4:00 pm
Effector therapeutics to present at 2022 bio ceo & investor conference
SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pio...
February 9, 2022, 4:00 pm
Kodiak (kod) completes enrolling patients in retina-based studies
Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibit...
February 4, 2022, 1:45 pm
Kodiak (kod) completes enrolling patients in retina-based studies
Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibit...
February 4, 2022, 1:45 pm
Kodiak (kod) completes enrolling patients in retina-based studies
Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its VEGF inhibit...
February 4, 2022, 1:45 pm
Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...
February 3, 2022, 7:00 pm
Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...
February 3, 2022, 7:00 pm
Verona pharma: first inhaled product candidate combining anti-inflammatory and bronchodilator effects, a potential blockbuster
he company's lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is bein...
February 3, 2022, 7:00 pm